Hepatic gene therapy using lentiviral vectors: Has safety been established?
David Dismuke, R. Jude Samulski – 20 May 2013
Therapeutic advantage of anti‐VAP‐1 over anti‐α4 integrin antibody in concanavalin a‐induced hepatitis
Woo‐Yong Lee, Marko Salmi, Margaret M. Kelly, Sirpa Jalkanen, Paul Kubes – 17 May 2013 – Hepatitis induced by concanavalin A (Con A) in mice is well known to be a T‐lymphocyte‐mediated injury. It has been reported that T helper (Th)1 and Th2 lymphocytes use α4 integrin and vascular adhesion protein (VAP)−1, respectively, to adhere within the hepatic sinusoids. Therefore, we investigated whether inhibition of these molecules ameliorates or worsens the Con A‐induced hepatic injury in vivo.
Reply
Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada – 17 May 2013
Bevacizumab: Finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia
Lawrence H. Young, Katharine J. Henderson, Robert I. White, Guadalupe Garcia‐Tsao – 17 May 2013
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients
Mazen Noureddin, Katherine P. Yates, Ivana A. Vaughn, Brent A. Neuschwander‐Tetri, Arun J. Sanyal, Arthur McCullough, Raphael Merriman, Bilal Hameed, Edward Doo, David E. Kleiner, Cynthia Behling, Rohit Loomba, for the NASH CRN – 17 May 2013 – The characteristics of nonalcoholic fatty liver disease (NAFLD) in elderly patients are unknown. Therefore, we aimed to examine the differences between elderly and nonelderly patients with NAFLD and to identify determinants of nonalcoholic steatohepatitis (NASH) and advanced fibrosis (bridging fibrosis or cirrhosis) in elderly patients.
Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: Epidemiology and natural history
Mark Deneau, M. Kyle Jensen, John Holmen, Marc S. Williams, Linda S. Book, Stephen L. Guthery – 17 May 2013 – The epidemiology and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (AIH) are not well characterized. Using multiple, overlapping search strategies followed by a detailed records review, we identified all cases of pediatric PSC, ASC, AIH, and inflammatory bowel disease (IBD) in a geographically isolated region of the United States.
Adjuvant gemcitabine therapy improves survival in a locally induced, R0‐resectable model of metastatic intrahepatic cholangiocarcinoma
Engin Gürlevik, Bettina Fleischmann‐Mundt, Nina Armbrecht, Thomas Longerich, Norman Woller, Arnold Kloos, Dirk Hoffmann, Axel Schambach, Thomas C. Wirth, Michael P. Manns, Lars Zender, Stefan Kubicka, Florian Kühnel – 17 May 2013 – Complete surgical tumor resection (R0) for treatment of intrahepatic cholangiocarcinoma (ICC) is potentially curative, but the prognosis remains dismal due to frequent tumor recurrence and metastasis after surgery. Adjuvant therapies may improve the outcome, but clinical studies for an adjuvant approach are difficult and time‐consuming for rare tumor entities.
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis
Núria Guañabens, Anna Monegal, Dacia Cerdá, África Muxí, Laia Gifre, Pilar Peris, Albert Parés – 17 May 2013 – Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once‐weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared in a randomized, 2‐year study in 42 postmenopausal women with PBC and osteoporosis.
Adipose tissue‐derived stem cells as a regenerative therapy for a mouse steatohepatitis‐induced cirrhosis model
Akihiro Seki, Yoshio Sakai, Takuya Komura, Alessandro Nasti, Keiko Yoshida, Mami Higashimoto, Masao Honda, Soichiro Usui, Masayuki Takamura, Toshinari Takamura, Takahiro Ochiya, Kengo Furuichi, Takashi Wada, Shuichi Kaneko – 17 May 2013 – Cirrhosis is a chronic liver disease that impairs hepatic function and causes advanced fibrosis. Mesenchymal stem cells have gained recent popularity as a regenerative therapy since they possess immunomodulatory functions. We found that injected adipose tissue‐derived stem cells (ADSCs) reside in the liver.